Low-Dose Doxepin
- 1 August 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in CNS Drugs
- Vol. 24 (8), 713-720
- https://doi.org/10.2165/11200810-000000000-00000
Abstract
Doxepin binds with high specificity and affinity to the histamine H1 receptor compared with other receptors. Therefore, at low doses, doxepin selectively antagonises H1 receptors, which is believed to promote the initiation and maintenance of sleep. In three large, well designed, phase III trials in adult or elderly patients with chronic primary insomnia, oral, low-dose doxepin 3 or 6 mg once daily improved wake time after sleep onset, total sleep time and sleep efficiency to a significantly greater extent than placebo. Significant between-group differences in polysomnographic sleep recordings that favoured low-dose doxepin were evident after a single administration of the drug. Other efficacy measures, including patient-reported sleep quality, also favoured low-dose doxepin over placebo. Symptom control was maintained for up to 12 weeks of low-dose doxepin administration and there was no evidence of physical dependence or worsening insomnia after doxepin withdrawal. Oral, low-dose doxepin 6 mg was also significantly more effective than placebo in a large, well designed trial modelling transient insomnia in healthy adults, according to polysomnographic recordings (e.g. in latency to persistent sleep). Oral, low-dose doxepin was generally well tolerated in clinical trials.Keywords
This publication has 12 references indexed in Scilit:
- Single Dose Pharmacokinetics of Doxepin in Healthy VolunteersActa Pharmacologica et Toxicologica, 2009
- Efficacy and Safety of Doxepin 1 mg, 3 mg, and 6 mg in Elderly Patients With Primary InsomniaPublished by Physicians Postgraduate Press, Inc ,2008
- Diagnosis and treatment of insomniaAmerican Journal of Health-System Pharmacy, 2008
- Efficacy and Safety of Doxepin 1 mg, 3 mg, and 6 mg in Adults with Primary InsomniaSleep, 2007
- Novel therapeutic usage of low-dose doxepin hydrochlorideExpert Opinion on Investigational Drugs, 2007
- Treating the health, quality of life, and functional impairments in insomnia.2007
- The epidemiology and diagnosis of insomnia.2006
- Pharmacologic and Nonpharmacologic Treatments of InsomniaNeurologic Clinics, 2005
- The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomniaPsychopharmacology, 2003
- Nocturnal Melatonin Secretion and Sleep after Doxepin Administration in Chronic Primary InsomniaPharmacopsychiatry, 1996